ClinicalTrials.gg
CompletedNCT00958724Updated Jun 28, 2018Results posted

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

A Phase 1 interventional study of Neratinib and Vinorelbine in Advanced Malignant Solid Tumors, sponsored by Puma Biotechnology, Inc.. Completed at 2 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-06-28.

Sponsored by Puma Biotechnology, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The purposes of this study are to evaluate the safety and tolerability of neratinib in combination with vinorelbine at the maximum tolerated dose (MTD) determined in a previous study, or to determine a lower MTD of the two drugs, as well as to obtain preliminary information on whether the combination of the two drugs has any effect on solid tumors in Japanese patients.

02

Conditions studied

  • Advanced Malignant Solid Tumors

Keywords

  • HKI-272
  • Vinorelbine
  • Combination
  • Solid Tumor
  • Neratinib
  • Nerlynx
  • PB-272
03

In context

Lead sponsor

Puma Biotechnology, Inc. is the lead sponsor of 38 studies on the registry; 3 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed pathologic diagnosis of a solid tumor that is not curable with available therapies for which neratinib plus vinorelbine is a reasonable treatment option.
  • At least 1 as defined by .
  • performance status of 0 to 2 (not declining within 2 weeks before signing the form).
  • Recovery from all AEs related to prior therapies (excluding alopecia).
  • within the study site's limits of normal.
  • Screening laboratory values within the following parameters:

    • : 1.5 × 109/L
    • count: 100 × 109/L
    • : 9.0 g/dL
    • Serum creatinine: 1.5 ×
    • Total : 1.5 × ULN
    • and alanine aminotransferase: 2.5 × ULN (\<= 5 × ULN if liver are present).
  • For women of , a negative urine or serum pregnancy test result before study entry.
  • All female and male subjects who are biologically capable of having children must agree and commit to the use of a reliable method of for the duration of the study and for 28 days after the last dose of test article. A subject is biologically capable of having children if he or she is using contraceptives or if his or her sexual partner is sterile or using contraceptives.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with anthracyclines with a cumulative dose of doxorubicin of >400 mg/m\^2, or of epirubicin >800 mg/m\^2, or the equivalent dose for other anthracyclines or derivatives.
  • Major surgery, chemotherapy, radical (curative intent) radiotherapy, agents, or other cancer therapy within at least 2 weeks before treatment day 1.
  • Bone as the only site of disease.
  • Active central nervous system , as indicated by clinical symptoms, cerebral edema, and/or progressive growth. (Subjects with a history of or cord compression are allowable if they have been definitively treated and are off anticonvulsants and for at least 4 weeks before cycle 1 day 1) .
  • (QTc) interval > 0.47 s or a known history of QTc prolongation or Torsades de Pointes.
  • Presence of or uncontrolled cardiac disease, including congestive heart failure ( functional classification of =2), angina requiring treatment, myocardial infarction within the past 12 months, or any clinically significant supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention.
  • Pregnant or breastfeeding women. Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (eg, Crohn disease, malabsorption, or grade 2 diarrhea of any etiology at baseline).
  • Inability or unwillingness to swallow tablets (neratinib).
  • Preexisting grade 2 or greater motor or sensory neuropathy.
  • Subject known to be seropositive and/or have acute or chronic infection (hepatitis B surface antigen [HBsAg] positive) or infection (anti-HCV positive).
  • History of known to vinorelbine and any of its components.
  • Any other cancer within 5 years prior to screening with the exception of contralateral breast carcinoma, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.
  • Clinically significant ongoing or recent infection within 2 weeks before treatment day 1.
  • Evidence of significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, make the subject inappropriate for this study. Examples include, but are not limited to, serious active infection (ie, requiring intravenous antibiotic or antiviral agent) or uncontrolled major seizure.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Neratinib and Vinorelbine

    Neratinib: 240 mg administered daily by mouth continuously, Vinorelbine: 25 mg/m\^2 administered IV on Day 1 and 8 of 21 day cycle

    Drug: Neratinib · Drug: Vinorelbine

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    Number of participants experiencing DLT of neratinib in combination with vinorelbine in Japanese patients.

    Time frame: From first dose date to 21st day

Secondary outcomes

  1. Best Overall Response

    Best Overall Response in Evaluable Population per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: From first dose date to progression or last tumor assessment, up to 40 weeks.

  2. Duration of Objective Response

    The duration of objective response was measured from the time at which measurement criteria were met for Complete Response (CR) or Partial Response (PR) (whichever status was recorded first) until the first date on which recurrence or Progressive Disease (PD) was objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started.

    Time frame: From first response date to PD/death, up to 40 weeks.

  3. Objective Response Rate (ORR)

    Proportion of subjects who achieved complete response or partial response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: From first dose date to progression or last tumor assessment, up to 40 weeks.

  4. Progression Free Survival

    Number of weeks between the date of the first dose of test article and the first date of disease recurrence or progression, or death due to any cause, was documented, censored at the last evaluation, investigator assessment. Disease Progression (PD) is defined using Response Evaluation Criteria in Solid Tumors Criteria (v1.0), at least a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as reference the nadir LD, meaning the smallest sum of the LDs recorded since the treatment started; or unequivocal progression of existing nontarget lesions; or the appearance of any new lesions.

    Time frame: From first dose to last evaluation, up to 40 weeks.

  5. Area Under the Curve (AUC) Tau

    AUC of Neratinib at day 8 following administration of Neratinib 240 mg in combination with Vinorelbine 25 mg/m\^2 to Japanese Subjects with Cancer.

    Time frame: Predose, and hour 1, 2, 4, 6, 8 and 24 on day 8.

  6. Terminal-phase Elimination Half-life

    Terminal-phase elimination half-life of Neratinib at day 8 following Administration of Neratinib 240 mg in combination with Vinorelbine 25 mg/m\^2 to Japanese Subjects with Cancer.

    Time frame: Predose, and hour 1, 2, 4, 6, 8 and 24 on day 8.

07

Results

Posted Feb 26, 2018

Participant flow

Participant flow — Overall Study
MilestoneNera 240 + Vino 25
Started6
Completed0
Not completed6
Withdrew: Disease progression6

Outcome measures

PrimaryDose Limiting Toxicity (DLT)

Number of participants experiencing DLT of neratinib in combination with vinorelbine in Japanese patients.

Time frame:
From first dose date to 21st day
Reported as:
Number · participants
Dose Limiting Toxicity (DLT)
participantsNera 240 + Vino 25
Dose Limiting Toxicity (DLT)1
SecondaryBest Overall Response

Best Overall Response in Evaluable Population per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
From first dose date to progression or last tumor assessment, up to 40 weeks.
Reported as:
Count of participants · Participants
Best Overall Response
ParticipantsNera 240 + Vino 25
Partial Response1
Stable Disease >= 6 weeks5
Stable Disease >= 24 weeks1
SecondaryDuration of Objective Response

The duration of objective response was measured from the time at which measurement criteria were met for Complete Response (CR) or Partial Response (PR) (whichever status was recorded first) until the first date on which recurrence or Progressive Disease (PD) was objectively documented, taking as reference for PD the smallest measurements recorded since the treatment started.

Time frame:
From first response date to PD/death, up to 40 weeks.
Reported as:
Median · weeks
Duration of Objective Response
weeksNera 240 + Vino 25
Duration of Objective Response12.0 (NA to NA)
SecondaryObjective Response Rate (ORR)

Proportion of subjects who achieved complete response or partial response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
From first dose date to progression or last tumor assessment, up to 40 weeks.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsNera 240 + Vino 25
Objective Response Rate (ORR)16.7 (0.4 to 64.1)
SecondaryProgression Free Survival

Number of weeks between the date of the first dose of test article and the first date of disease recurrence or progression, or death due to any cause, was documented, censored at the last evaluation, investigator assessment. Disease Progression (PD) is defined using Response Evaluation Criteria in Solid Tumors Criteria (v1.0), at least a 20% increase in the sum of the longest diameters (LD) of target lesions, taking as reference the nadir LD, meaning the smallest sum of the LDs recorded since the treatment started; or unequivocal progression of existing nontarget lesions; or the appearance of any new lesions.

Time frame:
From first dose to last evaluation, up to 40 weeks.
Reported as:
Median · weeks
Progression Free Survival
weeksNera 240 + Vino 25
Progression Free Survival18.2 (18.0 to 24.1)
SecondaryArea Under the Curve (AUC) Tau

AUC of Neratinib at day 8 following administration of Neratinib 240 mg in combination with Vinorelbine 25 mg/m\^2 to Japanese Subjects with Cancer.

Time frame:
Predose, and hour 1, 2, 4, 6, 8 and 24 on day 8.
Reported as:
Mean · ng*hr/mL
Area Under the Curve (AUC) Tau
ng*hr/mLNera 240 + Vino 25
Area Under the Curve (AUC) Tau1330 ± 925
SecondaryTerminal-phase Elimination Half-life

Terminal-phase elimination half-life of Neratinib at day 8 following Administration of Neratinib 240 mg in combination with Vinorelbine 25 mg/m\^2 to Japanese Subjects with Cancer.

Time frame:
Predose, and hour 1, 2, 4, 6, 8 and 24 on day 8.
Reported as:
Mean · hr
Terminal-phase Elimination Half-life
hrNera 240 + Vino 25
Terminal-phase Elimination Half-life14.37 ± 3.41

Adverse events

Collected over From first dose through 28 days after last dose, up to 40 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nera 240 + Vino 25—1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventNera 240 + Vino 25
Peritoneal abscessInfections and infestations1/6
Most frequent other events
Showing 10 of 55
Most frequent other events
EventNera 240 + Vino 25
LeukopeniaBlood and lymphatic system disorders6/6
NeutropeniaBlood and lymphatic system disorders6/6
DiarrhoeaGastrointestinal disorders6/6
FatigueGeneral disorders5/6
PyrexiaGeneral disorders5/6
Decreased appetiteMetabolism and nutrition disorders5/6
NauseaGastrointestinal disorders4/6
StomatitisGastrointestinal disorders4/6
LymphopeniaBlood and lymphatic system disorders3/6
VomitingGastrointestinal disorders3/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Nera 240 + Vino 25
<=18 years0
Between 18 and 65 years5
>=65 years1
Age, Continuous
Age, Continuous(years)Nera 240 + Vino 25
Mean54 ± 13.37
Sex: Female, Male
Sex: Female, Male(Participants)Nera 240 + Vino 25
Female4
Male2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nera 240 + Vino 25
Japanese6
08

Study locations

2 sites
  • Shizuoka Cancer Center
    Shizuoka, 411-8777, Japan
  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research
    Tokyo, 135-8550, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2009 to primary completion in Apr 2010, 9 months.

Results were first posted in Feb 2018, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2009
First posted
Aug 13, 2009
StartActual
Jul 2009
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Feb 26, 2018
Last update
Jun 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00958724
Responsible party
Sponsor
First posted
Aug 13, 2009
Start date
Jul 2009
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Feb 26, 2018
Last update
Jun 28, 2018

Study contacts

Puma
study director · Biotechnology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neratinib

Start the discussion